Market Currents
Aeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor...
-
Monday, November 19, 2012, 2:09 PM ETAeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor perifosine, when combined with temsirolimus, was well tolerated while treating recurrent or progressive malignant glioma during Phase 1 clinical trials.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
